Long COVID-19 Syndrome: Phunziro Latsopano

KUGWIRITSA KWAULERE | eTurboNews | | eTN
Written by Linda Hohnholz

Kafukufuku wavomerezedwa ndi South African Health Authority kwa anthu omwe ali ndi matenda a COVID-19 omwe amakhala ndi zizindikiro zofooketsa zakuthupi komanso zamaganizo zomwe zimapitilira kwa milungu yopitilira 12 kachilomboka kadutsa.

PaxMedica, Inc., kampani ya biopharmaceutical yomwe imayang'ana kwambiri kupanga mankhwala omwe amathandizira kuthana ndi zovuta zakukhala ndi zovuta za minyewa, lero yalengeza kuti yalandira chivomerezo kuchokera ku South African Health Products Regulatory Agency (SAHPRA) kuti igwiritse ntchito mayeso achipatala Zotsatira za PAX-101 (suramin intravenous (IV) infusions) mwa odwala omwe ali ndi Long COVID-19 Syndrome (LCS), yomwe imadziwikanso kuti post-acute sequelae ya matenda a SARS-CoV-2.

Phunziroli, PAX-LCS-101, lidzakhala gawo la 1B, loyembekezeredwa, losasinthika, loyendetsedwa ndi placebo, lopanda khungu, lophunzira maulendo angapo. Kafukufukuyu akuyembekezeka kuyamba kulembetsa odwala m’gawo loyamba la chaka chino atalandira chivomerezo cha Komiti ya National Ethics Committee ya ku South Africa.

LCS ndi matenda oopsa, amitundumitundu omwe amabweretsa kuwonongeka kwakukulu kwa magwiridwe antchito mwa anthu ambiri atatenga kachilombo koyambitsa matenda a COVID-19. Kuzindikira kwa LCS ndikovuta chifukwa palibe mayeso enieni otsimikizira kuti ali ndi matendawa. Ngakhale pali matanthauzo ambiri omwe akuperekedwa m'mabuku azachipatala, ofufuza ambiri amatanthauzira LCS ngati matenda omwe amaphatikizapo njira yayitali ya zizindikiro zosiyanasiyana za thupi ndi ubongo zomwe zimapitirira kwa masabata a 12 kapena kuposerapo popanda kufotokozera kwina. Kafukufukuyu akuyembekezeka kulembetsa odwala omwe ali ndi zisonyezo zokhazikika za LCS, atadwala kale kachilombo ka COVID-19. Zizindikiro za LCS mwa wodwala aliyense zimatha kusiyana koma nthawi zambiri zimakhala kutopa, "chifunga chaubongo", kupweteka, kupweteka mutu, kupuma pang'ono, kuvutika maganizo ndi chidwi, kusokonezeka kwa kugona, orthostasis ndi chizungulire, ndi kuchepa kwa ntchito komanso zizindikiro zambiri zomwe zimagwirizana nazo. monga kupweteka pamodzi ndi minofu, kuvutika maganizo ndi nkhawa.

LCS yawonedwa kuti ikufanana kwambiri ndi vuto lina la post-acute lomwe limadziwika kuti myalgic encephalomyelitis / chronic fatigue syndrome (ME/CFS). M'matenda onsewa, kutopa ndi chizindikiro chodziwika bwino ndipo zizindikiro zina zambiri zimayenderana. Zinthu zonsezi zingayambitse kulephera kugwira ntchito kapena kuchita zinthu zabwinobwino ndipo zikavuta kwambiri za ME/CFS, zalembedwa kuti zikhale zaka zambiri, zomwe zimapangitsa kuti omwe akukhudzidwawo azikhala kunyumba, ngati sagona. PaxMedica ikukonzekera kuphunzira PAX-101 ngati chithandizo cha LCS ndi ME/CFS. 

Mayesero azachipatalawa akukonzekera kuti aphunzire za chitetezo ndi kulolera, mphamvu, ndi PK ya milingo iwiri ya suramin (5 mg/kg ndi 10 mg/kg) mwa akulu, zaka 18 ndi kupitirira, ndi LCS.

Ngakhale kuti chithandizo chamankhwala cha LCS sichinakwaniritsidwe, palibe mankhwala ovomerezeka a matendawa. Pali mgwirizano womwe ukukula pakati pa asayansi ndi azachipatala pakufunika kofufuza zambiri pazomwe zimayambitsa LCS, komanso vuto lomwe lingakhale lokhudzana ndi ME/CFS.

PAX-101 ilinso mu Phase 2 ya Autism Spectrum Disorder ("ASD"). Kampani ikupanganso PAX-102, kapangidwe kake ka m'mphuno ka suramin, ka ASD ndi matenda ena a neurologic.

ZOMWE MUNGACHITE PA NKHANIYI:

  • , a biopharmaceutical company focused on developing medicines that help overcome the challenges of living with complex neurological conditions, today announced that it has received approval from the South African Health Products Regulatory Agency (SAHPRA) for its clinical trial application to study the effects of PAX-101 (suramin intravenous (IV) infusions) in patients with Long COVID-19 Syndrome (LCS), also known as post-acute sequelae of SARS-CoV-2 infection.
  • The symptoms of LCS in each patient can vary but often include fatigue, “brain fog”, pain, headaches, shortness of breath, difficulty with concentration and attention, sleep disturbance, orthostasis and dizziness, and decreased functioning as well as many associated symptoms such as joint and muscle pain, depression and anxiety.
  • Although there are many definitions proposed in the medical literature, most researchers define LCS as a syndrome that includes a protracted course of various physical and neuropsychiatric symptoms that persist for 12 weeks or more without an alternative explanation.

<

Ponena za wolemba

Linda Hohnholz

Mkonzi wamkulu kwa eTurboNews zochokera ku eTN HQ.

Amamvera
Dziwani za
mlendo
0 Comments
Zolowetsa Pamakina
Onani ndemanga zonse
0
Mukufuna malingaliro anu, chonde yankhani.x
Gawani ku...